Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS200661-0007 in preschool children with urogenital schistosomiasis
PACTR202001553028239Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levopraziquantel in schistosomiasis haematobium and schistosomiasis, sponsored by Merck & Co. Primary endpoint: Clinical cure. Status: unknown.
02
Drugs
levopraziquantel
03
Conditions
schistosomiasis haematobiumschistosomiasis
Beyond the preview
Go deeper on PACTR202001553028239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202001553028239.